Cassie Wells
Family · Jasper, ALNPI 1063170843
Payments from drug & device makers
Across 112 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$224
- Otsuka America Pharmaceutical, Inc.$183
- Lilly USA, LLC$170
- Exact Sciences$169
- AstraZeneca$147
- Takeda Pharmaceuticals U.S.A., Inc.$133
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,074100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $224 |
| Otsuka America Pharmaceutical, Inc. | 10 | $183 |
| Lilly USA, LLC | 9 | $170 |
| Exact Sciences | 8 | $169 |
| AstraZeneca | 8 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $133 |
| Antares Pharma, Inc. | 5 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $89 |
| Tris Pharma Inc | 4 | $88 |
| Ardelyx, Inc. | 4 | $85 |
| Bayer | 5 | $80 |
| Axsome Therapeutics, Inc. | 4 | $68 |
| Corcept Therapeutics | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Novo Nordisk | 3 | $52 |
| Corium, LLC | 3 | $50 |
| Tolmar, Inc. | 3 | $47 |
| Pfizer | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Dexcom, Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Amgen | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $15 |
How this compares
$2,074 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $14,790 |
| EliquisApixaban | 16 | $13,830 |
| Desloratadine | 20 | $741 |
| Montelukast Sodium | 40 | $690 |
| Pantoprazole Sodium | 49 | $654 |
| Duloxetine Hcl | 21 | $612 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $544 |
| Rosuvastatin Calcium | 15 | $529 |
| Atorvastatin Calcium | 41 | $458 |
| Levothyroxine Sodium | 26 | $399 |
| Pravastatin Sodium | 17 | $371 |
| Metoprolol Succinate | 15 | $367 |
| Celecoxib | 11 | $317 |
| Methocarbamol | 16 | $287 |
| Glipizide ErGlipizide | 15 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $52 | $14,79014 claims |
| PfizerEliquis | $36 | $13,83016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.
Other family in Jasper
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.